Verzögerte AMNOG-Rückerstattung
Definition
In kollaborativen Forschungsabkommen mit Kliniken oder Krankenkassen dauern AMNOG-Bewertungen Monate, was zu vorläufigen niedrigen Preisen oder NUB-Status 2 (keine Garantie) führt.
Key Findings
- Financial Impact: €10M+ pro RCT-Studie bei NUB-Versagen; 1 Jahr Wartezeit auf volle Erstattung
- Frequency: Jährlich pro Projekt
- Root Cause: Komplexe HTA-Dossiers und G-BA-Anforderungen ohne frühe Abstimmung
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Nanotechnology Research.
Affected Stakeholders
Forschungsleiter, CFO, Reimbursement Manager
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
E-Rechnungsmandat in Forschungsabrechnungen
Hohe NUB-Antrags- und RCT-Kosten
IP-Entschädigungsstreitigkeiten in Verträgen
Leerlauf durch Inventarengpässe
GoBD-Verstöße bei Kalibrierungsdokumentation
Leerlauf von Nanotechnologie-Ausrüstung
Request Deep Analysis
🇩🇪 Be first to access this market's intelligence